版本:
中国

BRIEF-Recro Pharma announces successful top-line results from phase III safety study of iv meloxicam

May 9 Recro Pharma Inc

* Recro pharma announces successful top-line results from phase iii safety study of iv meloxicam

* Recro pharma inc - iv meloxicam 30mg continues to demonstrate solid safety and tolerability profile

* Recro pharma inc - company on track to file nda with u.s. Fda in early q 3 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐